Comparative effectiveness of tumor necrosis factor agents and disease-modifying antirheumatic therapy in children with enthesitis-related arthritis: The first year after diagnosis

Pamela F. Weiss, Rui Xiao, Timothy G. Brandon, Ilaria Pagnini, Tracey B. Wright, Timothy Beukelman, Esi Morgan-DeWitt, Chris Feudtner

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: To characterize the effect of anti-tumor necrosis factor (TNF) therapy compared to conventional synthetic disease-modifying antirheumatic drugs (csDMARD) in children with enthesitis-related arthritis (ERA) over the first year after diagnosis. Methods: We conducted a multicenter retrospective comparative effectiveness study of children diagnosed with ERA. We estimated the effect of anti-TNF therapy on clinical variables (active joint count, tender entheses count) and patient-reported pain and global assessment of disease activity over the first year after diagnosis using state-of-the-art comparative effectiveness analytic methods. Results: During the study period, 217 patients newly diagnosed with ERA had a total of 965 clinic visits the first year after disease diagnosis. Children [median age 11.6 yrs, interquartile range 10-14] were treated with anti-TNF monotherapy (n = 33, 15.2%), csDMARD monotherapy (n = 73, 33.6%), or both (n = 52, 23.9%) in the first year after disease diagnosis. There was a statistically significant improvement in the primary outcome, active joint count, over time in children who received an anti-TNF drug versus those who did not (p = 0.03). Additionally, use of anti-TNF therapy versus no anti-TNF therapy was associated with less patient-reported pain (p < 0.01) and improved disease activity over time as assessed by the clinical Juvenile Arthritis Disease Activity Score (p < 0.01). The magnitude of estimated effect on clinical outcomes was uniformly greater, with the exception of tender entheses count, in children treated with an anti-TNF drug versus a csDMARD. Conclusion: During the first year after diagnosis, anti-TNF exposure was associated with benefits for several clinically meaningful outcomes in children with enthesitis-related arthritis.

Original languageEnglish (US)
Pages (from-to)107-114
Number of pages8
JournalJournal of Rheumatology
Volume45
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Arthritis
Tumor Necrosis Factor-alpha
Antirheumatic Agents
Therapeutics
Joints
Juvenile Arthritis
Pain Measurement
Ambulatory Care
Pharmaceutical Preparations
Pain

Keywords

  • Anti-tumor necrosis factor agents
  • Enthesitis-related arthritis conventional synthetic disease-modifying antirheumatic drugs

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Comparative effectiveness of tumor necrosis factor agents and disease-modifying antirheumatic therapy in children with enthesitis-related arthritis : The first year after diagnosis. / Weiss, Pamela F.; Xiao, Rui; Brandon, Timothy G.; Pagnini, Ilaria; Wright, Tracey B.; Beukelman, Timothy; Morgan-DeWitt, Esi; Feudtner, Chris.

In: Journal of Rheumatology, Vol. 45, No. 1, 01.01.2018, p. 107-114.

Research output: Contribution to journalArticle

Weiss, Pamela F. ; Xiao, Rui ; Brandon, Timothy G. ; Pagnini, Ilaria ; Wright, Tracey B. ; Beukelman, Timothy ; Morgan-DeWitt, Esi ; Feudtner, Chris. / Comparative effectiveness of tumor necrosis factor agents and disease-modifying antirheumatic therapy in children with enthesitis-related arthritis : The first year after diagnosis. In: Journal of Rheumatology. 2018 ; Vol. 45, No. 1. pp. 107-114.
@article{3223a0fdbf014f32aab23dcec0e1b146,
title = "Comparative effectiveness of tumor necrosis factor agents and disease-modifying antirheumatic therapy in children with enthesitis-related arthritis: The first year after diagnosis",
abstract = "Objective: To characterize the effect of anti-tumor necrosis factor (TNF) therapy compared to conventional synthetic disease-modifying antirheumatic drugs (csDMARD) in children with enthesitis-related arthritis (ERA) over the first year after diagnosis. Methods: We conducted a multicenter retrospective comparative effectiveness study of children diagnosed with ERA. We estimated the effect of anti-TNF therapy on clinical variables (active joint count, tender entheses count) and patient-reported pain and global assessment of disease activity over the first year after diagnosis using state-of-the-art comparative effectiveness analytic methods. Results: During the study period, 217 patients newly diagnosed with ERA had a total of 965 clinic visits the first year after disease diagnosis. Children [median age 11.6 yrs, interquartile range 10-14] were treated with anti-TNF monotherapy (n = 33, 15.2{\%}), csDMARD monotherapy (n = 73, 33.6{\%}), or both (n = 52, 23.9{\%}) in the first year after disease diagnosis. There was a statistically significant improvement in the primary outcome, active joint count, over time in children who received an anti-TNF drug versus those who did not (p = 0.03). Additionally, use of anti-TNF therapy versus no anti-TNF therapy was associated with less patient-reported pain (p < 0.01) and improved disease activity over time as assessed by the clinical Juvenile Arthritis Disease Activity Score (p < 0.01). The magnitude of estimated effect on clinical outcomes was uniformly greater, with the exception of tender entheses count, in children treated with an anti-TNF drug versus a csDMARD. Conclusion: During the first year after diagnosis, anti-TNF exposure was associated with benefits for several clinically meaningful outcomes in children with enthesitis-related arthritis.",
keywords = "Anti-tumor necrosis factor agents, Enthesitis-related arthritis conventional synthetic disease-modifying antirheumatic drugs",
author = "Weiss, {Pamela F.} and Rui Xiao and Brandon, {Timothy G.} and Ilaria Pagnini and Wright, {Tracey B.} and Timothy Beukelman and Esi Morgan-DeWitt and Chris Feudtner",
year = "2018",
month = "1",
day = "1",
doi = "10.3899/jrheum.170251",
language = "English (US)",
volume = "45",
pages = "107--114",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "1",

}

TY - JOUR

T1 - Comparative effectiveness of tumor necrosis factor agents and disease-modifying antirheumatic therapy in children with enthesitis-related arthritis

T2 - The first year after diagnosis

AU - Weiss, Pamela F.

AU - Xiao, Rui

AU - Brandon, Timothy G.

AU - Pagnini, Ilaria

AU - Wright, Tracey B.

AU - Beukelman, Timothy

AU - Morgan-DeWitt, Esi

AU - Feudtner, Chris

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: To characterize the effect of anti-tumor necrosis factor (TNF) therapy compared to conventional synthetic disease-modifying antirheumatic drugs (csDMARD) in children with enthesitis-related arthritis (ERA) over the first year after diagnosis. Methods: We conducted a multicenter retrospective comparative effectiveness study of children diagnosed with ERA. We estimated the effect of anti-TNF therapy on clinical variables (active joint count, tender entheses count) and patient-reported pain and global assessment of disease activity over the first year after diagnosis using state-of-the-art comparative effectiveness analytic methods. Results: During the study period, 217 patients newly diagnosed with ERA had a total of 965 clinic visits the first year after disease diagnosis. Children [median age 11.6 yrs, interquartile range 10-14] were treated with anti-TNF monotherapy (n = 33, 15.2%), csDMARD monotherapy (n = 73, 33.6%), or both (n = 52, 23.9%) in the first year after disease diagnosis. There was a statistically significant improvement in the primary outcome, active joint count, over time in children who received an anti-TNF drug versus those who did not (p = 0.03). Additionally, use of anti-TNF therapy versus no anti-TNF therapy was associated with less patient-reported pain (p < 0.01) and improved disease activity over time as assessed by the clinical Juvenile Arthritis Disease Activity Score (p < 0.01). The magnitude of estimated effect on clinical outcomes was uniformly greater, with the exception of tender entheses count, in children treated with an anti-TNF drug versus a csDMARD. Conclusion: During the first year after diagnosis, anti-TNF exposure was associated with benefits for several clinically meaningful outcomes in children with enthesitis-related arthritis.

AB - Objective: To characterize the effect of anti-tumor necrosis factor (TNF) therapy compared to conventional synthetic disease-modifying antirheumatic drugs (csDMARD) in children with enthesitis-related arthritis (ERA) over the first year after diagnosis. Methods: We conducted a multicenter retrospective comparative effectiveness study of children diagnosed with ERA. We estimated the effect of anti-TNF therapy on clinical variables (active joint count, tender entheses count) and patient-reported pain and global assessment of disease activity over the first year after diagnosis using state-of-the-art comparative effectiveness analytic methods. Results: During the study period, 217 patients newly diagnosed with ERA had a total of 965 clinic visits the first year after disease diagnosis. Children [median age 11.6 yrs, interquartile range 10-14] were treated with anti-TNF monotherapy (n = 33, 15.2%), csDMARD monotherapy (n = 73, 33.6%), or both (n = 52, 23.9%) in the first year after disease diagnosis. There was a statistically significant improvement in the primary outcome, active joint count, over time in children who received an anti-TNF drug versus those who did not (p = 0.03). Additionally, use of anti-TNF therapy versus no anti-TNF therapy was associated with less patient-reported pain (p < 0.01) and improved disease activity over time as assessed by the clinical Juvenile Arthritis Disease Activity Score (p < 0.01). The magnitude of estimated effect on clinical outcomes was uniformly greater, with the exception of tender entheses count, in children treated with an anti-TNF drug versus a csDMARD. Conclusion: During the first year after diagnosis, anti-TNF exposure was associated with benefits for several clinically meaningful outcomes in children with enthesitis-related arthritis.

KW - Anti-tumor necrosis factor agents

KW - Enthesitis-related arthritis conventional synthetic disease-modifying antirheumatic drugs

UR - http://www.scopus.com/inward/record.url?scp=85040036365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040036365&partnerID=8YFLogxK

U2 - 10.3899/jrheum.170251

DO - 10.3899/jrheum.170251

M3 - Article

C2 - 28916542

AN - SCOPUS:85040036365

VL - 45

SP - 107

EP - 114

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 1

ER -